Protein-protein interactions as drug targets

Topics in Medicinal Chemistry

Volumn 8, Issue , 2012, Pages 1-56

  Wendt, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Drug discovery; Inhibitors; Protein surface; Protein protein interactions

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ACYLPHENYLALANINE; BASILIXIMAB; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINEDIONE; CHEMICAL COMPOUND; DACLIZUMAB; EPTIFIBATIDE; FTSZ PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MI 219; NAVITOCLAX; NUTLIN 3; OXINDOLE; PHENYLALANINE DERIVATIVE; PROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; SD 304; SP 4206; SPD 304; SPIROOXINDOLE; TDP 222669; TMC 353121; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE; WK 23; Z INTERACTING PROTEIN A;

ARTICLE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULE; NEOPLASM; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS;

EID: 84864060444     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/978-3-642-28965-1_1     Document Type: Article

References (283)

1. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730
2. Russ AP, Lampel S (2006) The druggable genome: an update. Drug Disc Today 10:1607-1610
3. Overington JP, Al-Lazikani B, Hopkins AL (2008) How many drug targets are there? Nat Rev Drug Discov 5:993-996
4. Grant A, Lee D, Orengo C (2004) Progress towards mapping the universe of protein folds. Genome Biol 5:107
5. Kunin V, Cases I, Enrigh E, de Lorenzo V, Ouzounis CA (2003) Myriads of protein families, and still counting. Genome Biol 4:401
6. Vitkup D, Melamud E, Moult J, Sander C (2001) Completeness in structural genomics. Nat Struct Biol 8:559-566
7. Stumpf M, Thorne T, de Silva ERS et al (2008) Estimating the size of the human interactome. Proc Natl Acad Sci USA 105:6959-6964
8. Ideker T, Sharan R (2008) Protein networks in disease. Genome Res 18:644-652
9. Strong M, Eisenberg D (2007) The protein network as a tool for finding novel drug targets. Prog Drug Res 64:191-215
10. Komurov K, White M (2007) Revealing static and dynamic modular architecture of the eukaryotic protein interaction network. Mol Syst Biol 3:110
11. Aggarwal S (2009) Whats fueling the biotech engine - 2008. Nat Rev Immunol 11:987-993
12. Toogood PL (2002) Inhibition of protein-protein association by small-molecules: approaches and progress. J Med Chem 45:1543-1558
13. Chene P (2006) Drugs targeting protein-protein interactions. ChemMedChem 1:400-411
14. Whitty A, Kumaravel G (2006) Between a rock and a hard place? Nat Chem Biol 2:112-118
15. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3:301-317
16. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001-1009
17. Fischer PM (2005) Protein-protein interactions in drug discovery. Drug Des Rev Online 2:179-207
18. Berg T (2008) Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Dev 11:666-674
19. Fry DC (2008) Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Protein Pept Sci 9:240-247
20. Stites WE (1997) Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem Rev 97:1233-1250
21. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1-14
22. Young L, Jernigan RL, Covell DG (1994) A role for surface hydrophobicity in proteinprotein recognition. Protein Sci 3:717-729
23. Lo Conte L, Chothia C, Janin J (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285:2177-219824
24. Archakov AI, Govorun VM, Dubanov AV et al (2003) Protein-protein interactions as a target for drugs in proteomics. Proteomics 3:380-391
25. Keskin O, Gursoy A, Ma B, Nussinov R (2008) Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev 108:1225-1244
26. Tsai CJ, Lin SL, Wolfson HJ, Nissinov R (1997) Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci 6:53-64
27. Jones S, Thornton JM (1996) Principles of protein-protein interactions. Proc Natl Acad Sci USA 93:13-20
28. Jones S, Thornton JM (1997) Analysis of protein-protein interaction sites using surface patches. J Mol Biol 272:121-132
29. Argos P (1988) An investigation of protein subunit and domain interfaces. Protein Eng 2:101-113
30. Janin J, Miller S, Chothia C (1988) Surface, subunit interfaces and interior of oligomeric proteins. J Mol Biol 204:155-164
31. Bordner AJ, Abagyan R (2005) Statistical analysis and prediction of protein-protein interfaces. Proteins 60:353-366
32. Kufareva I, Budagyan L, Raush E et al (2007) PIER: protein interface recognition for structural proteomics. Proteins 67:400-417
33. Hu Z, Ma B, Wolfson H, Nussinov R (2000) Conservation of polar residues as hot spots at protein interfaces. Proteins 39:331-342
34. Fauchere JL, Pliska VE (1983) Hydrophobic parameters of amino-acid side-chains from the partitioning of N-acetyl-amino-acid amide. Eur J Med Chem 18:369-375
35. Radzicka A, Wolfenden R (1988) Comparing the polarities of the amino acids: side-chain distribution coefficients between the vapor phase, cyclohexane, 1-octanol, and neutral aqueous solution. Biochemistry 27:1664-1670
36. Takano K, Yutani K (2001) A new scale for side-chain contribution to protein stability based on the empirical stability analysis of mutant proteins. Protein Eng 14:525-528
37. Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267:383-386
38. Wells JA (1991) Systematic mutational analyses of protein-protein interfaces. Methods Enzymol 202:390-411
39. Atwell S, Ultsch M, de Vos AM, Wells JA (1997) Structural plasticity in a remodeled proteinprotein interface. Science 278:1125-1128
40. Jonsson Z, Podust V, Podust L, Hubscher U (1995) Tyrosine 114 is essential for the trimeric structure and the functional activities of human proliferating cell nuclear antigen. EMBO J 14:5745-5751
41. Sattler M, Liang H, Nettesheim D et al (1997) Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983-986
42. Hajduk PJ, Huth JR, Fesik SW (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48:2518-2525
43. Kozakov D, Hall DR, Chuang G et al (2011) Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci USA 108:13528-13535
44. DeLano WL (2002) Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 12:14-20
45. Ma B, Elkayam T, Wolfson H, Nussinov R (2003) Protein-protein interactions: structurally conserved residues distinguish between protein binding sites and exposed protein surfaces. Proc Natl Acad Sci USA 100:5772-5777
46. Sundberg EJ, Mariuzza RA (2000) Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Structure 8:R137-R142
47. Morrison KL, Weiss GA (2001) Combinatorial alanine scanning. Curr Opin Chem Biol 5:302-307
48. Sidhu SS, Fairbrother WJ, Deshayes K (2003) Exploring protein-protein interactions with phage display: discovery of peptidic antagonists of IGF-1 function. Chembiochem 4:14-25
49. Deshayes K (2005) Exploring protein-protein interactions using peptide libraries displayed on phage. In: Sidhu SS (ed) Phage display in biotechnology and drug discovery. CRC Press, Boca Raton
50. Hajduk PJ, Huth JR, Tse C (2005) Predicting protein druggability. Drug Discov Today 10:1675-1682
51. Burgoyne MJ, Jackson RM (2006) Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. Bioinformatics 22:1335-1342
52. Sugaya N, Furuya T (2011) Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions. BMC Bioinformatics 12:50
53. Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutriex BO (2010) Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov Today 15:656-667
54. Fuller JC, Burgoyne MJ, Jackson RM (2009) Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 14:155-161
55. Hopkins A, Groom C, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430-431
56. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10:464-469
57. Higuerelo AP, Schreyer A, Bickerton GRJ et al (2009) Atomic interactions and profile of small-molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des 74:457-467
58. Lipinski C, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25
59. Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 88:807-814
60. Johnson TW, Dress KR, Edwards M (2009) Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett 19:5560-5564
61. Morelli X, Bourgeas R, Roche P (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol 15:475-481
62. Reynès C, Host H, Camproux A et al (2010) Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol 6: e1000695
63. Neugebauer A, Hartmann RW, Klein CD (2007) Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J Med Chem 50:4665-4668
64. Oprea TI, Davis AM, Teague SJ, Leeson PD (2001) Is there a difference between leads and drugs? A historical perspective. J Chem Inf Model 41:1308-1315
65. Rishton GM (2003) Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 8:86-96
66. Teague SJ, Davis AM, Leeson PD, Oprea TI (1999) The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 38:3743-3748
67. Veber DF, Johnson SR, Cheng H-Y et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623
68. Bergstrom CAS, Strafford M, Lazarova L et al (2003) Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558-570
69. Hou TJ, Wang JM, Zhang W et al (2006) Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem 13:2653-2667
70. Hou T, Wang J, Zhang W, Xu X (2007) ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J Chem Inf Model 47:460-463
71. Alex A, Millan DS, Perez M et al (2011) Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. MedChemComm 2:669-674
72. Paolini GV, van Shepland RHB, Hoorn WP et al (2006) Global mapping of pharmacological space. Nat Biotechnol 24:805-815
73. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881-890
74. Wenlock MC, Austin RP, Barton P et al (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256
75. Walters WP, Green J, Weiss JR, Murcko MA (2011) What do medicinal chemists actually make? A 50-year retrospective. J Med Chem 54:6405-6416
76. Leeson PD, Davis AM (2004) Time-related differences in the physical property profiles of oral drugs. J Med Chem 47:6338-6348
77. Proudfoot JR (2005) The evolution of synthetic oral drug properties. Bioorg Med Chem Lett 15:1087-1090
78. Blake JF (2005) Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med Chem 1:649-655
79. Gill AL, Verdonk M, Boyle RG, Taylor R (2007) A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem 7:1408-1422
80. Bergstrom CAS, Wassvik CM, Johansson K, Hubatsch I (2007) Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 50:5858-5862
81. Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:1000-1017
82. Vintinoiu A, Leroux JC (2008) Organogels and their use in drug delivery: a review. J Control Release 125:179-192
83. Gupta S, Moulik SP (2008) Biocompatible microemulsions and their prospective uses in drug delivery. J Pharm Sci 97:22-45
84. Cheng Y, Xu Z, Ma M, Xu T (2008) Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 97:123-143
85. Drummond DC, Noble CO, Hayes ME et al (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97:4696-4740
86. Breitenbach J (2002) Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 54:107-117
87. DeLano WL, Ultsch MH, deVos AM, Wells JA (2000) Convergent solutions to binding at a protein-protein interface. Science 287:1279-1283
88. Eyrisch S, Helms V (2007) Transient pockets on protein surfaces involved in protein-protein interaction. J Med Chem 50:3457-3464
89. Ma B, Shatsky M, Wolfson HJ, Nussinov R (2002) Multiple diverse ligands binding at a single protein site: a matter of preexisting populations. Protein Sci 11:184-197
90. Teague S (2003) Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2:527-541
91. Kortemme T, Kim DE, Baker D (2004) Computational alanine scanning of protein-protein interfaces. Sci Signal 219:l2
92. McGovern SL, Caselli E, Grigorieff N, Shoichet BK (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45:1712-1722
93. Seidler J, McGovern SL, Dornan TL, Shoichet BK (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 46:4477-4786
94. Lebowicz J, Lewis MS, Schuck P (2009) Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci 11:2067-2079
95. Arkin M, Lear JD (2001) A new data analysis method to determine binding constants of small-molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. Anal Biochem 299:98-107
96. Philo JS (2000) Sedimentation equilibrium analysis of mixed associations using numerical constraints to impose mass or signal conservation. Methods Enzymol 321:100-120
97. Leavitt S, Freire E (2001) Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol 11:560-566
98. Lewis EA, Murphy KP (2005) Isothermal titration calorimetry. Methods Mol Biol 305:1-15
99. Pattnaik P (2000) Surface plasmon resonance. Applications in understanding receptor-ligand interaction. Appl Biochem Biotechol 126:79-92
100. Cooper M, Mayr LM, Rich RL, Myszka DG (2011) The revolution of real-time, label-free biosensor applications. In: Cooper M, Mayr LM (eds) Label-free technologies for drug discovery. Wiley, New York
101. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534
102. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211-219
103. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragmentbased drug discovery. J Med Chem 51:3661-3680
104. Sun C, Petros AM, Hajduk PJ (2011) Fragment-based lead discovery: challenges and opportunities. J Comput Aided Mol Des 25:607-610
105. Coyne AG, Scott DE, Abell C (2010) Drugging challenging targets using fragment-based approaches. Curr Opin Chem Biol 14:299-307
106. Hamalainen MD, Zhukov A, Ivarsson M et al (2008) Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J Biomol Screen 13:202-209
107. Pellecchia M, Bertini I, Cowburn D et al (2008) Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov 7:738-745
108. Navratilova I, Hopkins AL (2010) Fragment screening by surface plasmon resonance. ACS Med Chem Lett 1:44-48
109. Neumann T, Junker HD, Schmidt K, Sekul R (2007) SPR-based fragment screening: advantages and applications. Curr Top Med Chem 7:1630-1642
110. Nienaber VL, Richardson PL, Klighofer V et al (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18:1105-1108
111. Davies DR, Begley DW, Hartley RC et al (2011) Predicting the success of fragment screening by X-ray crystallography. Methods Enzymol 493:91-114
112. Jhoti H, Cleasby A, Verdonk M, Williams G (2008) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11:485-493
113. Hajduk PK, Gerfin T, Boehlen JM et al (1999) High-throughput nuclear magnetic resonancebased screening. J Med Chem 42:2315-2317
114. Dalvit C, Flocco M, Knapp S et al (2002) High-throughput NMR-based screening with competition binding experiments. J Am Chem Soc 124:7702-7709
115. Hajduk PJ, Burns DJ (2002) Integration of NMR and high-throughput screening. Comb Chem High Throughput Screen 6:613-621
116. Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1:45-54
117. Blundell TL, Patel S (2004) High-throughput X-ray crystallography for drug discovery. Curr Opin Pharmacol 4:490-496
118. Koppen H (2009) Virtual screening - what does it give us? Curr Opin Drug Discov Dev 12:397-407
119. Cavasotto CN, Orry AJW (2007) Ligand docking and structure-based virtual screening in drug discovery. Curr Opin Med Chem 7:1006-1014
120. Betzi S, Restouin A, Opi S et al (2007) Protein-protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nef protein. Proc Natl Acad Sci USA 104:19256-19261
121. Casey FP, Pihan E, Shields DC (2009) Discovery of small-molecule inhibitors of proteinprotein interactions using combined ligand and target score normalization. J Med Chem 49:2708-2717
122. Sandrini S (2005) Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 19:705-710
123. Brandhuber BJ, Boone T, Kenney WC, McKay DB (1987) Three-dimensional structure of interleukin-2. Science 238:1707-1709
124. Sauve K, Nachman M, Spence C et al (1991) Localization in human interleukin 2 of the binding site to the a chain (p55) of the interleukin 2 receptor. Proc Natl Acad Sci USA 88:4636-4640
125. Tilley JW, Chen L, Fry DC et al (1997) Identification of a small-molecule inhibitor of the IL-2/IL-2Ra receptor interaction which binds to IL-2. J Am Chem Soc 119:7589-7590
126. Erlanson DA, Wells JA, Braisted AC (2004) Tethering: fragment-based drug discovery. Annu Rev Biophys 33:199-223
127. Hyde J, Braisted AC, Randal M, Arkin MR (2003) Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2. Biochemistry 42:6475-6483
128. Raimundo BC, Oslob JD, Braisted AC et al (2004) Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J Med Chem 47:3111-3130
129. Thanos CD, DeLano WL, Wells JA (2006) Hot-spot mimicry of a cytokine receptor by a small-molecule. Proc Natl Acad Sci USA 103:15422-15427
130. Rickert M, Wang X, Boulanger MJ et al (2005) The structure of interleukin-2 complexed with its alpha receptor. Science 308:1477-1480
131. Arkin MR, Randal M, DeLano WL et al (2003) Binding of small-molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 100:1603-1608
132. Siddiqui MA, Perry CM (2006) Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66:1263-1271
133. Monie A, Hung CF, Roden R, Wu TC (2008) Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2:97-105
134. Hebner CM, Laimins LA (2006) Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16:83-97
135. White PW, Faucher AM, Goudreau N (2011) Small-molecule inhibitors of the human papillomavirus E1-E2 interaction. Curr Top Microbiol Immunol 348:61-88
136. Yoakim C, Ogilvie WW, Goudreau N et al (2003) Discovery of the first series of inhibitors of human papilloma virus type 11: inhibition of the assembly of the E1-E2 Origin DNA complex. Bioorg Med Chem Lett 13:2539-2541
137. White PW, Titolo S, Brault K et al (2003) Inhibition of human papillomavirus DNA replication by small-molecule antagonists of the E1-E1 protein interaction. J Biol Chem 278:26765-26772
138. Wang Y, Coulombe R, Cameron DR et al (2004) Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 279:6976-6985
139. Goudreau N, Cameron DR, Deziel R et al (2007) Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg Med Chem 15:2690-2700
140. White PW, Faucher AM, Goudreau N (2011) Small-molecule inhibitors of the human papillomavirus E1-E2 interaction. In: Vassilev L, Fry D (eds) Small-molecule inhibitors of protein-protein interactions. Springer, Berlin
141. Antson AA, Burns JE, Moroz OV et al (2000) Structure of the intact transactivation domain of the human papillomavirus E2 protein. Nature 403:805-809
142. Harris SF, Botchan MR (1999) Crystal structure of the human papillomavirus type 18 E2 activation domain. Science 284:1673-1677
143. Abbate E, Berger JM, Botchan MR (2004) The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Dev 18:1981-1996
144. Mosyak L, Zhang Y, Glasfeld E et al (2000) The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography. EMBO J 19:3179-3191
145. Tsao DHH, Sutherland AG, Jennings LD et al (2006) Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg Med Chem 14:7953-7961
146. Jennings LD, Foreman KW, Rush TS et al (2004) Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorg Med Chem 12:5115-5131
147. Kenny CH, Ding W, Kelleher K et al (2003) Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Anal Biochem 323:224-233
148. Rush TS, Grant JA, Mosyak L, Nicholls A (2005) A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48:1489-1495
149. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223-241
150. Kussie PH, Gorina S, Marechal V et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953
151. Lin J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235-1246
152. Picksley SM, Vojtesek B, Sparks A, Lane DP (1994) Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523-2529
153. Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science 303:844-848
154. Grasberger BL, Lu T, Schubert C et al (2005) Discovery and cocrystal structure of benzodiazapinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48:909-912
155. Allen JG, Bourbeau MP, Wohlhieter GE et al (2009) Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem 52:7044-7053
156. Demma M, Maxwell E, Ramos R et al (2010) SCH529074, a small-molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 285:10198-10212
157. Yin H, Lee GI, Park HS et al (2005) Terphenyl-based helical mimetics that disrupt the p53/ HDM2 interaction. Angew Chem Int Ed Engl 44:2704-2707
158. Stoll R, Renner C, Hansen S et al (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-344
159. Lu Y, Nikolovska-Coleska Z, Fang X et al (2006) Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 49:3759-3762
160. Bowman AL, Nikolovska-Coleska Z, Zhong H et al (2007) Small-molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J Am Chem Soc 129:12809-12814
161. Rothweiler U, Czarna A, Krajewski M et al (2008) Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem 3:1118-1128
162. Fry DC, Graves B, Vassilev LT (2005) Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. Methods Enzymol 399:622-633
163. Ding K, Lu Y, Nikolovska-Coleska Z et al (2006) Structure-based design of spire-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49:3432-3435
164. Boettcher A, Buschmann N, Furet P et al (2008) 3-Imidazolylindoles for treatment of proliferative diseases and their preparation. PCT Int Appl WO2008119741
165. Popowicz GM, Czarna A, Wolf S et al (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9:1104-1111
166. Popowicz GM, Domling A, Holak TA (2011) The structure-based design of Mdm2-p53 inhibitors gets serious. Angew Chem Int Ed Engl 50:2680-2688
167. Uhrinova S, Uhrin D, Powers H et al (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350:587-598
168. Tovar C, Rosinski J, Filipovic Z et al (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888-1893
169. Shangary S, Qin D, McEachern D et al (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105:3933-3938
170. Weber L (2010) Patented inhibitors of p53-Mdm2 interaction (2006-2008). Expert Opin Ther Patents 20:179-191
171. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8:25-37
172. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59
173. Petros AM, Nettesheim DG, Wang Y et al (2000) Rationale for Bcl-x(L)/bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9:2528-2534
174. Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl family proteins induces regression of solid tumours. Nature 435:677-681
175. Lee EF, Czabotar PE, Smith BJ et al (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711-1713
176. Park C-M, Bruncko M, Adickes J et al (2008) Discovery of an orally bioavailable smallmolecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51:6902-6915
177. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL (2003) Anti-TNF-a therapies: the next generation. Nat Rev Drug Discov 2:736-746
178. Eck ME, Sprang SR (1989) The structure of tumor necrosis factor-a at 2.6A resolution. J Biol Chem 264:17595-17605
179. He MM, Smith AS, Oslb JD et al (2005) Small-molecule inhibition of TNF-a. Science 310:1022-1025
180. Debnath AK (2006) Prospects and strategies for the discovery and development of smallmolecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins. Curr Opin Investig Drugs 7:118-127
181. Debnath A (2006) Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1. Expert Opin Investig Drugs 15:465-478
182. Koszalka GW, Meanwell NA (2006) Inhibition of virus entry: an antiviral mechanism of emerging prominence. Curr Opin Investig Drugs 7:106-108
183. Roymans D, De Bondt HL, Arnoult E et al (2010) Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci USA 107:308-313
184. Pawson T, Scott JD (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278:2075-2080
185. Shimaoka M, Springer TA (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2:703-716
186. Scarborough RM, Gretler DD (2000) Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem 43:3453-3473
187. Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8:215
188. Duggan ME, Hutchinson JH (2000) Ligands to the integrin receptor avb3. Expert Opin Ther Patents 10:1367-1383
189. Cox D, Brennan M, Moran N (2010) Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9:804-820
190. Cox D (2004) Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 10:1587-1596
191. Auzzas L, Zanardi F, Battistini L et al (2010) Targeting avb3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. Curr Med Chem 17:1255-1299
192. Xiong JP, Stehle T, Diefenbach B et al (2001) Crystal structure of the extracellular segment of integrin avb3. Science 294:339-345
193. Xiong JP, Stehle T, Zhang R et al (2002) Crystal structure of the extracellular segment of integrin avb3 in complex with an arg-gly-asp ligand. Science 296:151-155
194. Springer TA, Zhu J, Xiao T (2008) Structural basis for distinctive recognition of fibrinogen gC peptide by the platelet integrin aIIbb3. J Cell Biol 182:791-800
195. Polman CH, OConnor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 354:899-910
196. Targan SR, Feagan BG, Fedorak RN et al (2007) Natalizumab for the treatment of active Crohns disease: results of the ENCORE trial. Gastroenterology 132:1672-1683
197. Tilley JW (2008) Very late antigen-4 integrin antagonists. Expert Opin Ther Patents 18:841-859
198. Muro F, Iimura S, Sugimoto Y et al (2009) Discovery of trans-4-[1-[[2,5-dichloro-4- (1-methyl-3-indolylcarboxamide)phenyl]acetyl]-(4 S)-methoxy-(2 S)-pyrrolidinylmethoxy] cyclo-hexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. J Med Chem 52:7974-7992
199. Faull RJ, Ginsberg MH (1996) Inside-out signaling through integrins. J Am Soc Nephrol 7:1091-1097
200. Qin J, Vinogradova O, Plow EF (2004) Integrin bidirectional signaling: a molecular view. PLoS Biol 2:0726-0729
201. Liu G (2001) Small-molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin Ther Patents 11:1383-1393
202. Potin D, Launay M, Monatlik F et al (2006) Discovery and development of 5-[(5S,9R)-9- (4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7- triazaspiro[4.4]non-7- ylmethyl]-3-thiophenecarboxylic acid (BMS-587101) - a small-molecule antagonist of leukocyte function associated antigen-1. J Med Chem 49:6946-6949
203. Kallen J, Welzenbach K, Ramage P et al (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 292:1-9
204. Shimaoka M, Salas A, Yang W et al (2003) Small-molecule integrin antagonists that bind to the b2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19:391-402
205. Welzenbach K, Hommel U, Weitz-Schmidt G (2002) Small-molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem 277:10590-10598
206. Miller MW, Basra S, Kulp DW et al (2009) Small-molecule inhibitors of integrin a2b1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci USA 106:719-724
207. Choi S, Vilaire G, Marcinkiewicz C et al (2007) Small-molecule inhibitors of integrin a2b1. J Med Chem 50:5457-5462
208. Russell RB, Breed J, Barton GJ (1992) Conservation analysis and structure prediction of the SH2 family of phosphotyrosine binding domains. FEBS Lett 304:15-20
209. Kasembeli MM, Xu X, Tweardy DJ (2009) SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front Biosci 14:1010-1022
210. Gan W, Roux B (2009) Binding specificity of SH2 domains: insight from free energy simulations. Proteins 74:996-1007
211. Songyang Z, Shoelson SE, Chaudhuri M et al (1993) Sh2 domains recognize specific phosphopeptide sequences. Cell 72:767-778
212. Songyang Z, Oelson SE, McGlade J et al (1994) Specific motifs recognized by the sh2 domains of csk, 3bp2, fps/fes, grb-2, hcp, shc, syk, and vav. Mol Cell Biol 14:2777-2785
213. Campbell SJ, Jackson RM (2003) Diversity in the SH2 domain family phosphotyrosyl peptide binding site. Protein Eng 16:217-227
214. Sawyer TK, Bohacek RS, Dalgarno DC et al (2002) Src homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev Med Chem 2:475-488
215. Lu XL, Cao X, Liu XY, Jiao BH (2010) Recent progress of Src SH2 and SH3 inhibitors as anticancer agents. Curr Med Chem 17:1117-1124
216. Shakespeare WC (2001) SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 5:409-415
217. Violette SM, Guan W, Bartlett C et al (2001) Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone 28:54-64
218. Shakespeare W, Yang M, Bohacek R (2001) Structure-based design of an osteoclastselective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA 97:9373-9378
219. Shakespeare WC, Metcalf CA III, Wang Y et al (2003) Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Dev 6:729-741
220. Lange G, Lesuisse D, Deprez P et al (2003) Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of pp 60Src are identical to those for high affinity binding of full length inhibitors. J Med Chem 46:5184-5195
221. Garcia-Echeverria C, Furet P, Gay B et al (1998) Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2) -X+1-Asn-NH2. J Med Chem 41:1741-1744
222. Schoepfer J, Fretz H, Gay B et al (1999) Highly potent inhibitors of the Grb2-SH2 domain. Bioorg Med Chem Lett 9:221-226
223. Gay B, Suarez S, Caravatti G et al (1999) Selective Grb2 inhibitors as anti-Ras therapy. Cell 83:235-241
224. Yao ZJ, Richter CR, Cao T et al (1999) Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 42:25-35
225. Gao Y, Luo J, Yao ZJ et al (2000) Inhibition of Grb2 SH2 domain binding by non-phosphatecontaining ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J Med Chem 43:911-920
226. Park IH, Li C (2009) Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation. J Mol Recognit 24:254-265
227. Huang N, Nagarsekar A, Xia G et al (2004) Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY+3 binding site. J Med Chem 47:3502-3511
228. Hung AY, Sheng M (2002) PDZ domains: structural modules for protein complex assembly. J Biol Chem 277:5699-5702
229. Harris BZ, Lim WA (2001) Mechanism and role of PDZ domains in signaling complex assembly. J Cell Sci 114:3219-3231
230. Tonikian R, Zhang Y, Sazinsky SL et al (2008) A specificity map for the PDZ domain family. PLoS Biol 6:e239
231. Stiffler MA, Chen JR, Grantcharova VP et al (2007) PDZ domain binding selectivity is optimized across the mouse proteome. Science 317:364-369
232. Doyle DA, Lee A, Lewis J et al (1996) Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85:106-1076
233. Kurakin A, Swistowski A, Wu SC, Bredesen DE (2007) The PDZ domain as a complex adaptive system. PLoS One 2:e953
234. Ducki S, Bennett E (2009) Protein-protein interactions: recent progress in the development of selective PDZ inhibitors. Curr Chem Biol 3:146-158
235. Wong HC, Bourdelas A, Krauss A et al (2003) Direct binding of the PDZ domain of dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 12:1251-1260
236. Zhang Y, Appleton BA, Wiesmann C et al (2009) Inhibition of Wnt signaling by dishevelled PDZ peptides. Nat Chem Biol 5:217-219
237. Fujiu N, You L, Xu Z et al (2007) An antagonist of dishevelled protein-protein interaction suppresses b-catenin-dependent tumor cell growth. Cancer Res 67:573-579
238. Grandy D, Shan J, Zhang X et al (2009) Discovery and characterization of a small-molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284:16256-16263
239. Lee HJ, Wang NX, Shi DL, Zheng JJ (2009) Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled. Angew Chem Int Ed Engl 48:6448-6452
240. Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kB, inflammation and cancer. Nat Rev Cancer 10:561-574
241. Srinivasula SM, Hegde R, Saleh A et al (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410:112-116
242. Shiozaki EN, Chai J, Rigotti DJ et al (2003) Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 11:519-527
243. Du C, Fang M, Li Y et al (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42
244. Verhagen AM, Ekert PG, Pakusch M et al (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102:43-53
245. Liu Z, Sun C, Olejniczak ET et al (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408:1004-1008
246. Wu G, Chai J, Suber TL et al (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408:1008-1012
247. Chai J, Du C, Wu JW et al (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406:855-862
248. Kipp RA, Case MA, Wist AD et al (2002) Molecular targeting of inhibitors of apoptosis proteins based on small-molecule mimics of natural binding partners. Biochemistry 41:7344-7349
249. Zobel K, Wang L, Varfolomeev E et al (2006) Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 1:525-534
250. Peng Y, Sun H, Nikolovska-Coleska Z et al (2008) Design, synthesis and evaluation of potent and orally bioavailable diazabicyclic smac mimetics. J Med Chem 51:8158-8162
251. Sun H, Stuckey JA, Nikolovska-Coleska Z et al (2008) Structure-based design, synthesis, evaluation and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem 51:7169-7180
252. Oost TK, Sun C, Armstrong RC et al (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47:4417-4426
253. Park CM, Sun C, Olejniczak ET et al (2005) Non-peptidic small-molecule inhibitors of XIAP. Bioorg Med Chem Lett 15:771-775
254. Chauhan D, Neri P, Velankar M et al (2007) Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 109:1220-1227
255. Gaither A, Porter D, Yao Y et al (2007) A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 67:11493-11498
256. Huang Y, Rich RL, Myszka DG, Wu H (2003) Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J Biol Chem 278:49517-49522
257. Li L, Thomas RM, Suzuki H et al (2004) A small-molecule smac mimic potentiates TRAILand TNF-a-mediated cell death. Science 305:1471-1474
258. Bertrand MJ, Milutinovic S, Dickson KM et al (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30:689-700
259. Sun H, Nikolovska-Coleska Z, Lu J et al (2007) Design, synthesis and characterization of a potent, nonpeptide, cell-permeable, bivalent smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 129:15279-15294
260. Nikolovska-Coleska Z, Meagher JL, Jiang S et al (2008) Interaction of a cyclic, bivalent Smac mimetic with the X-linked inhibitor of apoptosis protein. Biochemistry 47:9811-9824
261. Sun C, Cai M, Meadows RP et al (2000) NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 275:33777-33781
262. Cherepanov P, Sun ZYJ, Rahman S et al (2005) Solution structure of the HIV-1 integrasebinding domain in LEDGF/p75. Nat Struct Mol Biol 12:526-532
263. Cherepanov P, Ambrosio ALB, Rahman S et al (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102:17308-17313
264. Maertens G, Cherepanov P, Pluymers Wet al (2003) LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 278:33528-33539
265. Christ F, Voet A, Marchand A et al (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6:442-448
266. Du L, Zhao Y, Chen J et al (2008) D77, one benzoic acid derivative, functions as a novel anti- HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun 375:139-144
267. De Luca L, Barreca ML, Ferro S et al (2009) Pharmacophore-based discovery of smallmolecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 4:1311-1316
268. De Luca L, Ferro S, Gitto R et al (2010) Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 18:7515-7521
269. Dey A, Chitsaz F, Abbasi A et al (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA 100:8758-8763
270. Wu SY, Lee AY, Hou SY et al (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 20:2383-2396
271. Wu SY, Chiang CM (2007) The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 282:13141-13145
272. Liu Y, Wang X, Zhang J et al (2008) Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails. Biochemistry 47:6403-6417
273. Vollmuth F, Blankenfeldt W, Geyer M (2009) Structures of the dual bromodomains of the P-TEFb-activatin protein Brd4 at atomic resolution. J Biol Chem 284:36547-36556
274. Myoshi S, Ooike S, Iwata K et al (2009) Antitumor agent. PCT Int Appl WO2009084693
275. Filippakopoulos P, Qi J, Picaud S et al (2010) Selective inhibition of BET bromodomains. Nature 468:1067-1073
276. Mertz JA, Conery AR, Bryant BM et al (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108:16669-16674
277. Delmore JE, Issa GC, Lemieux ME et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-myc. Cell 146:904-917
278. Chung C, Coste H, White JH et al (2011) Discovery and characterization of small-molecule inhibitors of the BET family bromodomains. J Med Chem 54:3827-3838
279. Nicodeme E, Jeffrey KL, Schaefer U et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468:1119-1123
280. Dawson MA, Prinjha RK, Dittman A et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478:529-533
281. Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13:e29
282. Chung C, Witherington J (2011) Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J Biomol Screen 16:1170-1185
283. Chung C, Dean AW, Woolven JM, Bamborough P (2012) Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem 55:576-586